Drug Type Antibody fusion proteins |
Synonyms Anti-fap/interleukin-2 fusion protein ro6874281, Simlukafusp alfa, AFAP-IL2V + [5] |
Target |
Mechanism FAP modulators(Fibroblast activation protein alpha modulators), IL-2Rβγ agonists(Interleukin-2 Rβγ agonists), Immunomodulators |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cervical Squamous Cell Carcinoma | Phase 2 | US | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | BE | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | FR | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | DE | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | IL | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | NZ | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | PL | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | RU | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | SG | 19 Feb 2018 | |
Cervical Squamous Cell Carcinoma | Phase 2 | KR | 19 Feb 2018 |
Phase 1 | Squamous Cell Carcinoma of Head and Neck Second line | 46 | mqthxkrdza(uzxuvimhqk) = hlpvjaouci phupvymneb (xigkeavblx ) View more | Negative | 16 Sep 2021 | ||
NCT03063762 (ASCO2021) Manual | Phase 1 | 69 | (Arm A) | quxsvpmeai(hmqfydriit) = ardylissko pgnjlrefme (uyxlykhlpq, 12.95 - 40.12) View more | Positive | 20 May 2021 | |
(Arm B) | quxsvpmeai(hmqfydriit) = ejmbjftgrz pgnjlrefme (uyxlykhlpq, 27.67 - 66.68) | ||||||
NCT02627274 (ESMO2018) Manual | Phase 1 | 16 | ihrcnhzgjj(dlpqpqxakr) = mild or moderate pkpnnqohtf (xlqfljejgo ) View more | Positive | 20 Oct 2018 |